抗逆转录病毒治疗启动后体重增加:随机对照临床试验中的危险因素
结果显示体重增加在近期试验和较新ART方案中更明显,整合酶抑制剂(尤其是dolutegravir和bictegravir)、rilpivirine及tenofovir alafenamide与更多体重增加相关。
要点
- 整合酶抑制剂比蛋白酶抑制剂或NNRTI与更多体重增加相关。
- dolutegravir和bictegravir比elvitegravir/cobicistat体重增加更多。
- tenofovir alafenamide比tenofovir disoproxil fumarate、abacavir或zidovudine体重增加更多。
核心结论
- 体重增加在ART启动临床试验中普遍存在且由多因素导致,人口学因素、HIV相关因素和ART方案组成均有贡献。
- 某些ART药物差异性地促进体重增加的机制尚不清楚。
研究设计与样本
- 使用多变量模型探讨人口学因素、HIV疾病特征和ART组分与ART启动后体重变化的关系。
主要发现
- 体重增加在更近期的试验和使用更新ART方案时更大。
- 与体重增加相关的基线人口学因素包括较低CD4细胞计数、较高HIV 1型RNA、无注射吸毒、女性和黑人种族。
- 整合酶链转移抑制剂使用比蛋白酶抑制剂或非核苷类逆转录酶抑制剂(NNRTI)与更多体重增加相关,dolutegravir和bictegravir比elvitegravir/cobicistat与更多体重增加相关。
- 在NNRTI中,rilpivirine比efavirenz与更多体重增加相关。
- 在核苷/核苷酸逆转录酶抑制剂中,tenofovir alafenamide比tenofovir disoproxil fumarate、abacavir或zidovudine与更多体重增加相关。
临床怎么用
- 启动ART时应关注体重变化,尤其使用整合酶抑制剂(dolutegravir、bictegravir)、rilpivirine或tenofovir alafenamide的患者。
- 对低CD4计数、高HIV RNA、女性或黑人患者,应加强体重监测和生活方式干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Initiation of antiretroviral therapy (ART) often leads to weight gain. While some of this weight gain may be an appropriate return-to-health effect, excessive increases in weight may lead to obesity. We sought to explore factors associated with weight gain in several randomized comparative clinical trials of ART initiation. METHODS: We performed a pooled analysis of weight gain in 8 randomized controlled clinical trials of treatment-naive people living with human immunodeficiency virus (HIV) initiating ART between 2003 and 2015, comprising >5000 participants and 10 000 person-years of follow-up. We used multivariate modeling to explore relationships between demographic factors, HIV disease characteristics, and ART components and weight change following ART initiation. RESULTS: Weight gain was greater in more recent trials and with the use of newer ART regimens. Pooled analysis revealed baseline demographic factors associated with weight gain including lower CD4 cell count, higher HIV type 1 RNA, no injection drug use, female sex, and black race. Integrase strand transfer inhibitor use was associated with more weight gain than were protease inhibitors or nonnucleoside reverse transcriptase inhibitors (NNRTIs), with dolutegravir and bictegravir associated with more weight gain than elvitegravir/cobicistat. Among the NNRTIs, rilpivirine was associated with more weight gain than efavirenz. Among nucleoside/nucleotide reverse transcriptase inhibitors, tenofovir alafenamide was associated with more weight gain than tenofovir disoproxil fumarate, abacavir, or zidovudine. CONCLUSIONS: Weight gain is ubiquitous in clinical trials of ART initiation and is multifactorial in nature, with demographic factors, HIV-related factors, and the composition of ART regimens as contributors. The mechanisms by which certain ART agents differentially contribute to weight gain are unknown.
引用
- Sax PE, Erlandson KM, Lake JE, et al. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clin Infect Dis. 2020. PMID: 31606734. doi:10.1093/cid/ciz999
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。